Saturday 17 October 2026
Export APVO’s income statement to Excel — free account
Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.62
0.08
−4.71%
Follow APVO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.89 | 3.05 | 3.57 | 3.75 | |
Current Ratio |
2.08 | 3.36 | 3.82 | 4.03 | |
Net Debt/EBITDA |
1.53 | 2.14 | 3.65 | 2.79 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.86 | 1.17 | 0.89 | 0.74 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.56) | (7.51) | (16.60) | (29.71) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.56) | (7.51) | (16.60) | (29.71) | |
Cash per Share |
8.19 | 13.69 | 68.52 | 93.56 | |
Shareholders Equity per Share |
5.05 | 10.95 | 55.09 | 77.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.05 | 10.95 | 55.09 | 77.26 | |
Free Cash Flow |
(5.45) | (7.96) | (5.24) | (6.69) | |
Working Capital |
5.61 | 11.22 | 17.03 | 17.04 | |
Net Current Asset Value |
2.32 | 7.69 | 13.27 | 13.05 | |
| Other line items | |||||
Average Payables |
2.03 | 2.34 | 1.06 | 2.88 | |
Average Assets |
15.07 | 14.12 | 21.39 | 21.07 | |
Average Common Equity |
6.28 | 5.07 | 11.07 | 10.91 |
Columns are period end dates